BioSpace News Archive

Eli Lilly and Company announced that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company’s Executive Committee, effective July 22, 2024.

Capricor Therapeutics today announced positive 3-year results from the ongoing HOPE-2 open-label extension (OLE) study with CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD).

Zymo Research, a leader in biotechnological advancement has launched a new nuclease called PureRec Duplex-Specific Nuclease that selectively digests double stranded DNA.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BE-101, a novel engineered B Cell medicine (BCM) being developed for the treatment of Hemophilia B.

In a GE HealthCare sponsored pharmaco-economic study published in peer-reviewed journal PLOS ONE, the incidence, prevalence, diagnostic pathways, and treatments of different patients with metastatic or recurrent breast cancer were analyzed using a combination of widely accepted statistical modelling methods.

Champions Oncology, Inc., a leader in the development of advanced preclinical oncology solutions, has announced a strategic partnership with Medicines Discovery Catapult, enhancing their combined capabilities in the expanding field of radiopharmaceutical therapeutics.

Formosa Laboratories, Inc., a leading API supplier and CDMO headquartered in Taiwan, has successfully completed its acquisition of SynChem, Inc...

Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced results from the two presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced a strategic collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health.

Saguaro Biosciences today announced the successful closing of a $3 million seed funding round, comprised of equity investments and non-dilutive grant funding. CellCarta Biosciences, alongside strategic investments fro